British Columbia lists Epclusa on public drug plan to treat all six genotypes of chronic hepatitis C infection

Yahoo Finance

21 March 2017 - British Columbia also broadens access for patients with less advanced disease who have other health conditions.

Gilead Sciences Canada today announced, effective 21 March 2017 , British Columbia will provide public access to Epclusa (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection. 

This listing will support patients to access curative therapy, and will advance Canada's efforts to achieving its World Health Organization commitment to eliminate hepatitis C by 2030.

Read Gilead press release

Michael Wonder

Posted by:

Michael Wonder